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School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, AustraliaA B S T R A C TObjective: To review the use of health-related quality-of-life (HRQOL)
instruments as patient-reported outcome in patients with rheumatoid
arthritis (RA) in studies that have been published in Chinese-speaking
populations. Methods: Overlapping searching strategy was used
using four publication databases: PubMed and EMBASE for English
publications and Wanfang and CNKI for Chinese publications. Entries
published between January 1, 1990, and July 31, 2014, were retrieved
and then reviewed independently by two researchers. The identiﬁed
studies were summarized according to information source, publishing
year, study location, and study type. The validation studies were
examined closely in terms of their sample sizes and psychometric
properties. Results: There were 99 studies from the databases
selected for review. Among the studies reviewed, most studies were
conducted in Mainland China. There was a clear overall increasing
trend in the number of studies in recent years. Generic instrumentsee front matter Copyright & 2015, International S
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.1016/j.vhri.2015.03.001
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ondence to: Shu-Chuen Li, School of Biomedical Scwere more frequently used by researchers outside China. Another
observation was that most instruments were used without previous
validation either in any Chinese-speaking population with RA or in
the speciﬁc country that it was used. Conclusions: The importance of
patient-reported quality of life as an outcome indicator in patients
with RA is more and more realized in Chinese-speaking regions
during the past two decades. To facilitate the use of HRQOL for better
management of patients, and improve the quality of research, there is
a strong need of validating the HRQOL instruments in more locations
with a larger population, more comprehensive validity, and potential
cross-cultural validation in future.
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Rheumatoid arthritis (RA) is a chronic systemic inﬂammatory
disorder characterized by inﬂammation in the synovium of joints,
malaise, morning stiffness, and fatigue. It is associated with
progressive joint destruction and, depending on the severity,
may be accompanied by systemic manifestations including lung
disease, rheumatoid nodules, and effects on the cardiovascular
system. Patients with RA tend to undergo exacerbations and
periods of remission. If left untreated, over the course of 10 to 20
years RA may lead to signiﬁcant disabilities and a severe reduction
in the patient’s quality of life. The prevalence of RA, at 0.5% to 1%
[1], is relatively constant in many populations, but factors such as
sex, race, and smoking status can cause a variation in this level
[2,3]. In China, RA is among the 10 main chronic diseases, with
increasing morbidity: from 8.6% in 2003 to 10.2% in 2008 [4].
According to the Second National Survey of Disabled Population
in China in 2006, arthritis is the second most common cause of
disability [5]. Although the data would include both osteoarthritis
and RA, RA would be expected to contribute signiﬁcantly to thisburden because of the higher proportion of older women (in whom
RA is more commonly encountered) and the substantially higher
drug treatment cost for RA. Considering that the total size of the
Chinese population with disabilities is more than 80 million, the
burden from RA could be enormous.
In recent years, the importance of measuring health-related
quality of life (HRQOL) has been increasingly recognized by
clinicians and policymakers to inform patient management and
policy decisions, especially in the management of patients with
chronic diseases [6]. For clinicians, by gathering needed data
about patients’ functioning and well-being not captured by other
clinical markers through HRQOL measurements, they could be
alerted to potential problems that require intervention. For
decision makers or policymakers, HRQOL measurements could
be the evidence when evaluating alternative treatments [7].
Generally speaking, HRQOL measures could be either patient
reported or clinician reported. As part of patient-reported out-
comes [8], measuring patient-reported HRQOL is especially
important for diseases, conditions, or treatment effects that are
known only to the patient but are of clinical relevance to theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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of pain. In this research, we focused on patient-reported HRQOL.
RA being a deteriorative chronic disease, as described above, it is
important to keep tracking over time the HRQOL reported by
patients with RA to assess disease progression as well as effective-
ness of treatment. In Western countries, besides the generic HRQOL
instruments, for example, short-form 36 health survey (SF-36) [9]
and its shorter versions, and the EuroQol ﬁve-dimensional ques-
tionnaire [10], many RA-speciﬁc HRQOL instruments such as the
health assessment questionnaire (HAQ) [11], the rheumatoid arthri-
tis quality of life [12], and Arthritis Impact Measurement Scales 2
(AIMS2) [13] have been created, validated, and then widely used in
clinical settings. In addition, the importance of measuring the
HRQOL is attested by the fact that the HAQ score was listed as a
component of the American College of Rheumatology criteria [14]
for diagnosing RA. There is no clear picture, however, how HRQOL
has been studied among Chinese-speaking patients with RA,
especially in Mainland China. Considering the sheer size of RA
sufferers in China alone, a clearer understanding of the current
status of HRQOL tools available for use among Chinese-speaking
patients with RA would contribute toward better management of
these patients. Better management of these patients is likely to
produce signiﬁcant health as well as economic beneﬁts.
In our present study, we aimed to review the development,
validation, and use of HRQOL instruments that have been
published globally in English and locally in Chinese as an out-
come measure in Chinese-speaking patients with RA, to address
three research questions:1. Which HRQOL instruments have been created and validated
for Chinese-speaking patients with RA?2. Which HRQOL instruments have been used to measure the
HRQOL of Chinese-speaking patients with RA?3. Have the HRQOL instruments been used appropriately after
sufﬁcient validation?Methods
Data Source
Electronic databases of PubMed and EMBASE, and Wanfang and
CNKI, which are the two leading Chinese publication databases,Fig. 1 – Flow chart of the selewere searched for English and Chinese publications, respectively.
The overlapping strategy of searching several electronic data-
bases was used to identify potentially relevant articles [15].
Time Frame
A time frame was set and all entries published between January
1, 1990, and July 31, 2014, were retrieved and analyzed. The ﬁnal
search of the databases concluded at August 1, 2014.
Searching Strategy
Studies were retrieved using a key word ﬁltration process. The
key words “(Rheumatoid Arthritis) AND (Quality of life) AND
(China OR Chinese)” were used to seek matches in the English
publication databases PubMed and EMBASE, while the corre-
sponding Chinese translations of “(Rheumatoid Arthritis) AND
(Quality of life)” were used to seek matches in the Chinese
publication databases Wanfang and CNKI. Considering the nature
of the Chinese publication databases, the translation of the key
word “(China OR Chinese)” was deemed unnecessary and hence
omitted and not used in the search.
Culling Criteria
After two researchers had independently read the titles,
abstracts, and full texts, if necessary, publications that had at
least one HRQOL instrument validated or used were included.
Even though no HRQOL instrument was mentioned, studies with
the American College of Rheumatology response rate were still
included because health assessment questionnaire – disability
index is part of the American College of Rheumatology response
criteria. In the culling process, because our objective was to
retrieve original prospective studies, reviews and retrospective
studies were excluded.
Qualitative Analysis
The identiﬁed RA studies were ﬁrst classiﬁed according to the
information source (publication in English/publication in Chi-
nese). Then, within each classiﬁcation, the retrieved studies were
further organized into different categories, according to year of
publication, location of study, and type of study (validation/
application). Furthermore, the number of publications of
each speciﬁc HRQOL instrument in the identiﬁed studies wasction process for articles.
Fig. 2 – Time distribution of studies with HRQOL instruments on patients with RA. HRQOL, health-related quality of life; RA,
rheumatoid arthritis.
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were identiﬁed. Considering the economic and social develop-
ment status, the location of study was categorized into two
classes: Mainland China and Other Chinese-speaking areas (Tai-
wan, Hong Kong, and Singapore). Finally, the validation studies
were examined closely in terms of their sample sizes, and the
psychometric properties, namely, internal consistency, test-
retest reliability, content validity, construct validity, criterion
validity, and responsiveness.Table 1 – Summary of studies reviewed.
Study attribute English
publication
(N ¼ 33)
Chinese
publication
(N ¼ 66)
Number of publications by year
1990–1995 0 0
1996–2000 1 1
2001–2005 4 3
2006–2010 13 27
2011–2014 15 35
Number of publications by country/area
Mainland China 17 66
Other (Taiwan, Hong
Kong, and
Singapore)
16 0
Type of study
Validation 4 3
Application 29 63Results
There were 45 and 58 English publications retrieved from PubMed
and EMBASE, respectively, and 267 and 157 Chinese publications
from Wanfang and CNKI, respectively. After deleting duplica-
tions, in total, 60 publications in English and 306 publications in
Chinese were retrieved from the electronic databases with the
use of the overlapping search strategy. After the culling process,
99 studies from the publication databases (33 in English and 66 in
Chinese) fulﬁlled the inclusion criteria and therefore were further
reviewed and classiﬁed (Fig. 1).
To evaluate the chronological change in the number of studies
on RA with HRQOL instruments, we grouped the studies in
chronological categories, namely, from 1990 to 1995, 1996 to
2000, 2001 to 2005, 2006 to 2010, and 2011 to 2013 (Fig. 2). There
is an overall trend consistent across the data sources: there was
clearly a sharp increase after 2005, and within less than 4 years
from 2011 to August 2014, the number of studies had overtaken
that of the previous 5 years (2006–2010).
Among the studies published in English, the number of
studies conducted in China (N ¼ 17) and other Chinese-
speaking countries/areas (N ¼ 16), including Taiwan, Hong Kong,
and Singapore, was comparable. It is not surprising, however,
that all studies published in Chinese (N ¼ 66) were conducted in
Mainland China. In terms of type of studies, it is consistent in
both English and Chinese publications that the number of studies
using the HRQOL instruments was much more than the number
of studies of validations on HRQOL instruments (Table 1).
A difference can be observed, however, in researchers’ pref-
erence of using the HRQOL instruments between Mainland China
and other Chinese-speaking areas. It could be seen from the
summary as presented in Table 2 that generic instruments were
more commonly used by researchers from other Chinese-
speaking areas, whereas disease-speciﬁc instruments seemed tobe preferred by researchers from Mainland China. To be more
speciﬁc, there were several instruments that were most fre-
quently used: the SF-36 and the HAQ in both Mainland China
and other Chinese-speaking areas, and Zung self-rating anxiety
scale/self-rating depression scale and the Rheumatoid Arthritis
Quality of Life Questionnaire (RAQOLQ) in Mainland China only.
Among the retrieved validation studies, there were
four instruments validated in Singapore—the EuroQol ﬁve-
dimensional questionnaire [16], the SF-36 [17], AIMS2 [18], and
the HAQ [19]—and three instruments, namely, the RAQOLQ [20],
Arthritis Impact Measurement Scales 2 Short Form [21], and the
Self Care Behavior Evaluation Questionnaire-Rheumatoid
Arthritis [22], validated in Mainland China.Discussion
In our present study, we attempted to review the extent of
adoption and application of the Chinese version of HRQOL
instruments in Chinese-speaking patients in the past two deca-
des by examining published articles reporting such use. Although
we did not retrieve any published article from 1990 to 1995, our
results show a trend of gradual increase in the number of
Table 2 – Summary of validation and use of HRQOL
instruments.
QOL
instrument
Mainland
China
Other (Taiwan, Hong
Kong, and Singapore)
Generic
EQ-5D 1 1* þ 1
SF-36 17 1* þ 7
SF-12 4 1
SF-6D 1
HUI 1
WHOQOL-BREF 3 1
WPAI:GH 1
FACIT-F 4
GDS 1
HADS 1
Zung SAS/SDS 15
SCL-90 1
HAMA/HAMD 1
Disease speciﬁc
HAQ 24 1* þ 4
RAQOLQ 1* þ 21
AIMS 1
AIMS2 2 1*
AIMS2-F 1*
SBCEQ-RA 1*
AIMS, Arthritis Impact Measurement Scales; AIMS2, Arthritis
Impact Measurement Scales 2; AIMS2-F, Arthritis Impact Measure-
ment Scales 2-Short Form; EQ-5D, EuroQol ﬁve-dimensional ques-
tionnaire; FACIT-F, Functional Assessment of Chronic Illness
Therapy-Fatigue; GDS, Geriatric Depression Scale; HADS, Hospital
Anxiety and Depression Scale; HAMA/HAMD, Hamilton Anxiety/
Hamilton Depression; HAQ, health assessment questionnaire;
HRQOL, health-related quality of life; HUI, health utilities index;
QOL, quality of life; RAQOLQ, Rheumatoid Arthritis Quality of Life
Questionnaire; SAS/SDS, self-rating anxiety scale/self-rating
depression scale; SBCEQ-RA; Self Care Behavior Evaluation Ques-
tionnaire-Rheumatoid Arthritis; SCL-90, Symptom Check List-90;
SF-36, short-form 36 health survey; SF-12, short-form 12 health
survey; SF-6D, six-dimensional health state short form (derived
from SF-36); WHOQOL-BREF, World Health Organization Quality of
Life - Abbreviation; WPAI:GH, Work Productivity and Activity
Impairment: General Health.
* Validation study.
Table 3 – Validation studies of HRQOL instruments in Ch
HRQOL
instrument
Validation
location
Sample size
Internal
consistency
Test-re
reliab
EQ-5D Singapore 22 X X
SF-36 Singapore 401 X X
HAQ Singapore 42 X X
AIMS2 Singapore 81 X X
AIMS2S-F Shanghai 51 X X
RAQOLQ Shanghai 50 X X
SBCEQ-RA Shanghai 48 X X
AIMS2, Arthritis Impact Measurement Scales 2; AIMS2-F, Arthritis Impact
questionnaire; HAQ, health assessment questionnaire; HRQOL, health-re
Arthritis Quality of Life Questionnaire; SBCEQ-RA, Self Care Behavior Ev
health survey.
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greater increase thereafter. This trend of increasing publication of
HRQOL articles in patients with RA is actually in line with the
gradual realization of the importance of incorporating HRQOL as
an outcome measure internationally. This also indicates that
the use of HRQOL instruments in patients with RA is gaining
more attention and better acceptance by clinicians and research-
ers for use in Chinese-speaking populations, particularly in
Mainland China.
Regarding the use of HRQOL instruments, different preferen-
ces of researchers from Mainland China and other Chinese-
speaking areas were observed. This may be partially explained
by the experience of use of the instruments by the researchers as
well as the relevance of the instruments for the setting; for
example, the RAQOLQ as an RA-speciﬁc instrument originally
developed in Chinese was used widely in Mainland China only.
Another possible explanation would be the availability of a
validated instrument (whether generic or disease speciﬁc) when
the study was performed. Actually this would explain another
observation that there were much more publications about the
application than the validation of the instruments, both in
English and in Chinese. Before being applied in studies or clinical
practice, it is mandatory that all HRQOL instruments should be
validated in terms of psychometric properties [23]. As shown in
the summary table (Table 1), however, application studies greatly
outnumbered validation studies. This may imply that most of the
instruments were used without previous validation in any
Chinese-speaking populations with RA. Another plausible
explanation may be that Chinese versions of some of these
generic instruments may be validated in other Chinese-
speaking patient groups and the general populations, but this is
still less than ideal.
First, as suggested in previous studies [23], to provide initial
estimates of reliability and validity, samples sizes should be at
least 200 cases, if feasible. Among the seven validation studies
conducted in either Singapore or China, the sample sizes were far
less than recommended, except for the validation study of the SF-
36 (Table 3). Second, although the reliability, including internal
consistency and test-retest reliability, was well performed in
these studies, the validations on validities and responsiveness
were comparably less well undertaken.
Last, before cross-cultural application of an HRQOL instru-
ment, there should be a cross-cultural validation and adaptation
to ensure level of comprehensibility and cognitive equivalence of
the translation on the same item across different cultures [24,25].
The EuroQol ﬁve-dimensional questionnaire, the SF-36, the HAQ,inese-speaking population with RA.
Psychometric property validated
test
ility
Content
validity
Construct
validity
Criterion
validity
Responsiveness
X
X X X
X X
X X X
X
X
X
Measurement Scales 2-Short Form; EQ-5D, EuroQol ﬁve-dimensional
lated quality of life; RA, rheumatoid arthritis; RAQOLQ, Rheumatoid
aluation Questionnaire-Rheumatoid Arthritis; SF-36, short-form 36
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RA but validated only in Singapore. Although there are no major
differences in the use of Chinese language itself between Singa-
pore and China, the economic development, culture, and living
conditions in these two countries are notably different. Singapore
is a multiracial country and among the most westernized among
the Asian countries. Hence, the Chinese-speaking population in
Singapore is likely to be inﬂuenced more by Western culture as
well as cultures of other major ethnic groups in Singapore.
Furthermore, being a developed economy with high incomes,
the expectation and response of the Singaporean population may
pose a subtle but important difference from populations in China
and Chinese-speaking populations in regions of lesser economic
development. All these could lead to a signiﬁcant difference in
patients’ understanding, appreciation, and response to the
HRQOL instrument. In fact, the same concerns also apply for
the three validation studies conducted in Mainland China: the
sample size of the studies was fairly small and data were
collected only in Shanghai, the largest and most developed city
in China. Considering the difference in economic development
and culture between major cities and vast rural regions, and
between south and north China, the data should be collected at
more than one location to increase the representativeness.
Conclusions
The importance of research and studies on patient-reported
HRQOL of patients with RA has been realized more and more in
China and the Chinese-speaking regions during the last two
decades. There still exist certain shortcomings, however, in the
validation of disease-speciﬁc instruments in particular for use in
clinical settings. To facilitate the clinical use of HRQOL in patients
with RA and improve the quality of research, there is a strong
need of validating the HRQOL instruments in more locations with
a larger population, more comprehensive validity, and potential
cross-cultural validation in future.
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